@article{cdd40ca04c33414bad1d52b68bfe3fad,
title = "Episodic disability questionnaire (EDQ) measurement properties among adults living with HIV in Canada, Ireland, United Kingdom, and United States",
abstract = "BACKGROUND: The Episodic Disability Questionnaire (EDQ) is a generic 35-item patient-reported outcome measure of presence, severity and episodic nature of disability. We assessed the measurement properties of the Episodic Disability Questionnaire (EDQ) with adults living with HIV.METHODS: We conducted a measurement study with adults living with HIV in eight clinical settings in Canada, Ireland, United Kingdom, and United States. We electronically administered the EDQ followed by three reference measures (World Health Organization Disability Assessment Schedule; Patient Health Questionnaire; Social Support Scale) and a demographic questionnaire. We administered the EDQ only 1 week later. We assessed the internal consistency reliability (Cronbach's alpha; > 0.7 acceptable), and test-retest reliability (Intra Class Correlation Coefficient; > 0.7 acceptable). We estimated required change in EDQ domain scores to be 95% certain that a change was not due to measurement error (Minimum Detectable Change (MDC95%)). We evaluated construct validity by assessing 36 primary hypotheses of relationships between EDQ scores and scores on the reference measures (> 75% hypotheses confirmed indicated validity).RESULTS: Three hundred fifty nine participants completed the questionnaires at time point 1, of which 321 (89%) completed the EDQ approximately 1 week later. Cronbach's alpha for internal consistency ranged from 0.84 (social domain) to 0.91 (day domain) for the EDQ severity scale, and 0.72 (uncertainty domain) to 0.88 (day domain) for the EDQ presence scale, and 0.87 (physical, cognitive, mental-emotional domains) to 0.89 (uncertainty domain) for the EDQ episodic scale. ICCs for test-retest reliability ranged from 0.79 (physical domain) to 0.88 (day domain) for the EDQ severity scale and from 0.71 (uncertainty domain) to 0.85 (day domain) for the EDQ presence scale. Highest precision was demonstrated in the severity scale for each domain (MDC95% range: 19-25 out of 100), followed by the presence (MDC95% range: 37-54) and episodic scales (MDC95% range:44-76). Twenty-nine of 36 (81%) construct validity hypotheses were confirmed.CONCLUSIONS: The EDQ possesses internal consistency reliability, construct validity, and test-retest reliability, with limited precision when administered electronically with adults living with HIV across in clinical settings in four countries. Given the measurement properties, the EDQ can be used for group level comparisons for research and program evaluation in adults living with HIV.",
keywords = "Adult, United States, Humans, Ireland, Reproducibility of Results, Canada, United Kingdom, Patient Reported Outcome Measures, HIV Infections",
author = "O'Brien, {Kelly K} and Erlandson, {Kristine M} and Brown, {Darren A} and Carusone, {Soo Chan} and Vera, {Jaime H} and Colm Bergin and Lisa Avery and Bayoumi, {Ahmed M} and Hanna, {Steven E} and Richard Harding and Patricia Solomon and Clair-Sullivan, {Natalie St} and Noreen O'Shea and Carolann Murray and Marta Boffito and {Da Silva}, George and Brittany Torres and Kiera McDuff and Davis, {Aileen M}",
note = "Funding Information: This research was supported the National Institute On Aging of the National Institutes of Health (NIH) (R21AG062380 and R01AG054366). Kelly K. O{\textquoteright}Brien was supported by a Canada Research Chair (Tier 2) in Episodic Disability and Rehabilitation from the Canada Research Chairs Program. Ahmed M. Bayoumi was supported by the Fondation Alma and Baxter Ricard Chair in Inner City Health at St. Michael{\textquoteright}s Hospital and the University of Toronto. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Canada Research Chairs Program, St. Michael{\textquoteright}s Hospital, or the University of Toronto. Funding Information: Kelly K. O{\textquoteright}Brien was supported by a Canada Research Chair (Tier 2) in Episodic Disability and Rehabilitation from the Canada Research Chairs Program. Ahmed M. Bayoumi was supported by the Fondation Alma and Baxter Ricard Chair in Inner City Health at St. Michael{\textquoteright}s Hospital and the University of Toronto. This research was supported by the National Institute On Aging of the National Institutes of Health (NIH) (R21AG062380 and R01AG054366). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Canada Research Chairs Program, St. Michael{\textquoteright}s Hospital, or the University of Toronto. Funding Information: We acknowledge the support from the clinical sites in facilitating recruitment and collection for this study (Casey House, Toronto; Department of Genitourinary Medicine and Infectious Diseases (GUIDE), St. James{\textquoteright}s Hospital, Dublin, Ireland; The University of Colorado Infectious Diseases Group Practice Clinic, University of Colorado, Denver, United States; Royal Sussex County Hospital, Brighton, United Kingdom; and the Chelsea and Westminster NHS Foundation Trust, London, United Kingdom, specifically the Kobler Rehabilitation Clinic, Chelsea and Westminster Hospital, 10 Hammersmith Broadway, 56 Dean Street, and West Middlesex University Hospital. Publisher Copyright: {\textcopyright} 2024, The Author(s).",
year = "2024",
month = jan,
day = "10",
doi = "10.1186/s12879-023-08958-7",
language = "English",
volume = "24",
pages = "71",
journal = "BMC infectious diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",
}
